MedPath

Ocedurenone

Generic Name
Ocedurenone
Clinical Trials
Related News

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

Phase 3
Terminated
Conditions
Chronic Kidney Diseases
Interventions
Drug: Placebo
First Posted Date
2021-07-20
Last Posted Date
2024-08-13
Lead Sponsor
KBP Biosciences
Target Recruit Count
652
Registration Number
NCT04968184
Locations
🇺🇸

Fides Clinical Research, Atlanta, Georgia, United States

🇺🇸

Allied Biomedical Research Institute, Miami, Florida, United States

🇺🇸

LCC Medical Research, Miami, Florida, United States

and more 208 locations

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-11-18
Last Posted Date
2024-02-23
Lead Sponsor
KBP Biosciences
Target Recruit Count
7
Registration Number
NCT04634812
Locations
🇺🇸

Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Phase 1
Completed
Conditions
Drug Drug Interaction
Healthy
Interventions
First Posted Date
2020-10-28
Last Posted Date
2024-02-23
Lead Sponsor
KBP Biosciences
Target Recruit Count
24
Registration Number
NCT04606537
Locations
🇺🇸

QPS Missouri, Springfield, Missouri, United States

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Phase 1
Completed
Conditions
Healthy
Moderate Hepatic Impairment
Interventions
First Posted Date
2020-09-01
Last Posted Date
2024-02-23
Lead Sponsor
KBP Biosciences
Target Recruit Count
12
Registration Number
NCT04534699
Locations
🇺🇸

Orlando Clinical Research Center (OCRC), Orlando, Florida, United States

🇺🇸

Clinical Trials of Texas (CTT), San Antonio, Texas, United States

🇺🇸

Texas Liver Institute (TLI), San Antonio, Texas, United States

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

Phase 1
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2016-07-19
Last Posted Date
2024-03-15
Lead Sponsor
KBP Biosciences
Target Recruit Count
11
Registration Number
NCT02837237
Locations
🇺🇸

KBP Biosciences USA Inc, Princeton, New Jersey, United States

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

Phase 1
Completed
Conditions
Healthy
Renal Insufficiency
Interventions
First Posted Date
2016-01-12
Last Posted Date
2024-04-15
Lead Sponsor
KBP Biosciences
Target Recruit Count
26
Registration Number
NCT02653014
Locations
🇺🇸

Research by Design, LLC, Evergreen Park, Illinois, United States

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-08-29
Last Posted Date
2024-02-23
Lead Sponsor
KBP Biosciences
Target Recruit Count
46
Registration Number
NCT02228733
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy